The Effects of Wellbutrin (Bupropion) on Residual and Cognitive Symptoms in SSRI-treated Depression
Summary
Many people with depression are treated with a serotonin-specific reuptake inhibitor anti-depressant (SSRI) and feel 'better'. Although many people feel 'better', they do not feel completely 'well'. Often, individuals continue to complain of cognitive problems such as lack of attention, diminished motivation, and impaired problem-solving. This study looks at whether residual and cognitive symptoms of depression in individuals are affected by the addition of Wellbutrin (bupropion).
Timeline
- Start
- 2005-08
- Primary completion
- 2010-01
- Completion
- 2011-12
Outcome
Mixed primary results
registry MEAN Wellbutrin First, Then Placebo: Follow-up at week 4: 12.0 (8.0 to 21.0) units on a scale NCT00125957 ↗
registry MEAN Placebo First, Then Wellbutrin: Follow-up at week 4: 14.0 (5.0 to 19.0) units on a scale NCT00125957 ↗
registry analysis (superiority or other test); Wellbutrin First, Then Placebo vs Placebo First, Then Wellbutrin; p = .04; Wilcoxon (Mann-Whitney) NCT00125957 ↗
registry analysis (superiority or other test); Wellbutrin First, Then Placebo vs Placebo First, Then Wellbutrin; p = 0.09; Wilcoxon (Mann-Whitney) NCT00125957 ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bupropion | Small molecule | 100 mg | — |
| Subject | Bupropion | Small molecule | 150 mg | — |